How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

809 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

741. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. (Abstract)

, was reported by 7% of patients in the clinic. Most patients (83%) graded transurethral alprostadil as causing minimal or no discomfort in the clinic. No patient reported priapism or developed penile fibrosis.Alprostadil delivered transurethrally by this system was well tolerated and effective in treating erectile dysfunction.

1998 British journal of urology Controlled trial quality: uncertain

742. Optimizing the therapeutic approach of transurethral alprostadil. (Abstract)

patients reported penile pain while treated with 500 microg than with 250 microg (P < 0.05) during the first 4 weeks. However, the penile pain was severe in very few men and it was a minor problem. Hypotensive symptoms were reported six times, independently of dose level. The administration of MUSE was generally rated as comfortable. No patients reported urethral stricture, penile fibrosis, or priapism either in the clinic or at home.Recommending 500 microg as a starting dose increased the percentage

2000 BJU international Controlled trial quality: uncertain

743. A clinical comparative study on effects of intracavernous injection of sodium nitroprusside and papaverine/phentolamine in erectile dysfunction patients. (Abstract)

, circumference and hardness after the administration of the experimental and control drugs were assessed and compared statistically.(1) There was no significant difference between the changes in penile length and circumference in the two occasions; (2) In 25 SNP and 28 control cases, the hardness of the penis was scored above 100 as evaluated by the Virag method (P > 0.05); (3) The duration of erection in the controls was longer than that in the SNP, but there were three priapism in the controls (...) and not a single one in the SNP; (4) there was no apparent change in the heart rate and blood pressure in both occasions; other side effects were minimal except slight local pain in a few controls.SNP facilitates relaxation of the penile smooth muscle and penile erection without significant side effects. SNP may be used in ED patients that experience pain and priapism with papaverine/phentolamine.

2000 Asian journal of andrology Controlled trial quality: uncertain

744. Intracavernous self-injection with phentolamine and papaverine for the treatment of impotence. (Abstract)

in 24 patients (82.8 per cent) and no erection occurred after injection of saline. Of the patients 12 (41.4 per cent) experienced technical difficulties with the injection. Ecchymosis of the penis at the site of injection was common and 1 patient experienced priapism that resolved spontaneously. No other side effects occurred. Intracavernous self-injection with phentolamine and papaverine appears to be a safe and effective treatment of impotence but long-term effects must be determined.

1987 The Journal of urology Controlled trial quality: uncertain

745. Comparative value of prostaglandin E1 and papaverine in treatment of erectile failure: double-blind crossover study among Egyptian patients. (Abstract)

was tolerable and transient, and the positive erectile response was not attended by priapism even in patients who formerly had priapism with papaverine hydrochloride. However, presently with prostaglandin E1 the relatively higher cost and shorter expiration period would probably limit its diagnostic and therapeutic use in Egypt, and probably in other developing countries.

1992 The Journal of urology Controlled trial quality: uncertain

746. Clinical safety profile of sildenafil in Singaporean men with erectile dysfunction: pre-marketing experience (ASSESS-I evaluation). (Full text)

(cardiovascular 3.3% in the present study versus 10.2% in the full ASSESS-I population; respiratory 3.3% versus 5.5%). All adverse events were transient and mild, and did not lead to treatment withdrawal. There was no effect on sitting blood pressure, heart rate or standard laboratory parameters; more importantly, there was no incidence of myocardial infarction, stroke or priapism. These results should reassure Singaporean patients and their physicians of the safety of sildenafil for erectile dysfunction.

2002 The Journal of international medical research Controlled trial quality: uncertain PubMed abstract

747. The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction. (Abstract)

The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction. Despite the introduction of sildenafil citrate many men with erectile dysfunction remain dependent on intracavernous therapy. While the majority achieves satisfactory results with currently available intracavernous preparations, all preparations have undesirable side effects, including priapism, fibrosis and post-injection pain. We determined the efficacy, safety and tolerability

2002 The Journal of urology Controlled trial quality: uncertain

748. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. (Abstract)

expected occurrence of priapism warrants clinicians asking directly about this side effect.

2001 Pharmacopsychiatry Controlled trial quality: uncertain

749. Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer

or nursing. Patients with history of priapism (persistant erections) and sickle cell anemia. Patients with a BMI(Body Mass Index) ≥ 35 Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT number): NCT00070148 Locations Layout table for location information United States

2003 Clinical Trials

750. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison. (Abstract)

Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison. The use of intracavernous prostaglandin E1 was studied in 48 organically impotent men. Eight men with previous chemical priapism did not have chemically induced priapism at up to 4 times the minimum effective dose of prostaglandin E1. Of 15 men with arteriogenic impotence who had failed prior intracavernous phentolamine and papaverine therapy 10 had adequate erections

1989 The Journal of urology

751. Medical treatment of impotence with papaverine and phentolamine intracavernosal injection. (Full text)

Medical treatment of impotence with papaverine and phentolamine intracavernosal injection. Intracavernosal injection of papaverine and phentolamine was used in 20 patients with impotence. After six months 14 patients were still using the self-injection treatment. Two patients failed to respond and two patients developed priapism which responded to venesection and metaraminol injection.

1990 The Ulster medical journal PubMed abstract

752. Biweekly intracavernous administration of papaverine for erectile dysfunction. (Full text)

Biweekly intracavernous administration of papaverine for erectile dysfunction. To determine the efficacy of the intracavernous administration of papaverine hydrochloride every 2 weeks to treat male impotence, we recruited 50 patients from a sexual dysfunction clinic. Of these, 8 did not complete the course of papaverine therapy. A total of 8 had complications, including priapism in 3 and ecchymoses or urethral bleeding in 5. In 30 patients who had substantial vasculogenic disease

1989 Western Journal of Medicine PubMed abstract

753. Prostaglandin E1 in the medical management of erectile dysfunction in a genito-urinary medicine clinic. (Full text)

continuing to use treatment successfully. The average dose was 14 micrograms (range 2.5 to 30 micrograms). There were no cases of priapism or cavernosal fibrosis and no systemic side effects. A low incidence (8%) of local discomfort was reported. We conclude that prostaglandin is a safe and effective vasoactive agent for the treatment of erectile failure in a genito-urinary outpatient clinic.

1994 The Ulster medical journal PubMed abstract

754. Sickle cell disease in Britain. (Full text)

chest syndrome. Comparison of clinical features in Brent and in Jamaica shows that the Brent patients with homozygous sickle cell anaemia are admitted with painful crises more frequently than Jamaican patients. However, the frequency of admissions for chest syndrome and priapism, and the incidence of splenomegaly are similar. Leg ulcers are uncommon in Brent. Patients with sickle cell haemoglobin C disease appeared more severely affected in Jamaica than in Brent. During the past two years 3165

1984 Journal of Clinical Pathology PubMed abstract

755. Heterogeneity of sickle-cell anemia based on a profile of hematological variables. (Full text)

significantly (P less than .05) for percent ever hospitalized for sickle-cell anemia, percent ever transfused, and percent with bone-age delays greater than 1 year. In addition, male clusters differed significantly for percent ever having had pneumonia, priapism, or dactylitis, and females differed significantly for height and weight. %Hb F and its inverse relationship with %HBA2 was more highly associated with the measures of severity than the degree of anemia or MCV. This study establishes the utility

1983 American Journal of Human Genetics PubMed abstract

756. 20-year experience with iatrogenic penile injury. (Abstract)

20-year experience with iatrogenic penile injury. We review our experience with the management of iatrogenic penile injuries. Apart from circumcision, serious damage to the penis can occur following hypospadias repair, surgery for priapism or total loss of the penis following surgical repair of bladder exstrophy.A retrospective analysis of patients with iatrogenic penile amputation referred to us between 1980 and 2000 was undertaken. Causes of injury and choice of management were reviewed.Of (...) the 13 cases treated during the 20-year period mechanism of primary injury was circumcision in 4, hypospadias repair in 6, priapism in 1, bladder exstrophy repair in 1 and penile carcinoma in 1. A variety of techniques were used for phallic reconstruction. Penile degloving, division of suspensory ligament and rotational skin flaps achieved penile augmentation and enhancement. Reasonable cosmesis and penile length were achieved in all cases. In indicated cases microsurgical phalloplasty

2003 Journal of Urology

757. priapism

priapism priapism - General Practice Notebook This site is intended for healthcare professionals General Practice Notebook | Medical search priapism Priapism is persistent painful erection in the absence of sexual desire. Links: General Practice Notebook General Practice Notebook The information provided herein should not be used for diagnosis or treatment of any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions

2010 GP Notebook

758. Treatments for priapism in boys and men with sickle cell disease. (Abstract)

Treatments for priapism in boys and men with sickle cell disease. Sickle cell disease comprises a group of genetic haemoglobin disorders. The predominant symptom associated with sickle cell disease is pain resulting from the occlusion of small blood vessels by abnormally 'sickle-shaped' red blood cells. There are other complications, including chronic organ damage and prolonged painful erection of the penis, known as priapism. Severity of sickle cell disease is variable, and treatment (...) is usually symptomatic. Priapism affects up to half of all men with sickle cell disease, however there is no consistency in treatment. We therefore need to know the best way of treating this complication in order to offer an effective interventional approach to all affected individuals.To assess the benefits and risks of different treatments for stuttering (repeated short episodes) and fulminant (lasting for six hours or more) priapism in sickle cell disease.We searched the Cochrane Cystic Fibrosis

2004 Cochrane

759. The management of priapism

The management of priapism Guidelines and Measures | Agency for Healthcare Research & Quality Search Search Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline Clearinghouse (NGC) has ended. Learn

2003 American Urological Association Education and Research, Inc.

760. Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia

Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia - Full Text View - Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Tadalafil for Treatment (...) of Priapism in Men With Sickle Cell Anemia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. Identifier: NCT00538564 Recruitment Status : Withdrawn (Trial closed just prior to study receiving Investigational Review Board approval) First Posted : October 2, 2007 Last Update Posted : September 21, 2016 Sponsor: Johns Hopkins

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>